Trevogrumab
Trevogrumab (REGN-1033) is a monoclonal antibody targeting GDF8 (growth differentiation factor 8, also known as myostatin) . Trevogrumab is used in research on muscle wasting conditions, including disuse atrophy, chronic diseases, and changes in food and nutrient intake[1][2][3].
Product Specifications
CAS Number
[1429201-24-0]
Product Name Alternative
REGN-1033
UNSPSC
12352203
Target
TGF-beta/Smad
Type
Inhibitory Antibodies
Related Pathways
Stem Cell/Wnt; TGF-beta/Smad
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/trevogrumab.html
Purity
99.77
Solubility
10 mM in DMSO
Smiles
[Trevogrumab]
Molecular Weight
(144.04 kDa)
References & Citations
[1]Masakazu Saitoh, et al. Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy. Volume2, Issue1, January 2017, Pages 1-10|[2]Mitra A, et al. The elusive role of myostatin signaling for muscle regeneration and maintenance of muscle and bone homeostasis. Osteoporos Sarcopenia. 2023 Mar;9 (1) :1-7.|[3]Latres E, et al. Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice. Skelet Muscle. 2015 Oct 9;5:34.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
